Shots:

• AstraZeneca to acquire all outstanding equity of Neogene for a total consideration of ~$320M incl. $200M up front & is eligible to receive ~$120M in milestones. The transaction is expected to close in Q1’23
• The acquisition will strengthen Neogene’s expertise in TCR-T discovery, development & manufacturing with AstraZeneca’s leadership in oncology for T-cell receptor therapies in solid tumors patients
• The goal of AstraZeneca's cell therapy portfolio is to strengthen & equip the T cells of the immune system for cancer. Research teams will develop off-the-shelf patient-ready therapies & are investigating new ways to target and arm CAR-Ts to increase their efficacy in solid tumors

Ref: Businesswire| Image: Neogene Therapeutics